Abstracts A189 perspective, more research is needed to identify the reasons for augmentation in children and adolescents with ADHD (e.g., duration of effect, titration) and to examine patterns of medication taking throughout the day.
PMH87 TREATMENT PATTERNS BY RACE/ETHNICITY AND INCOME LEVELS AMONG ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) SUBJECTS TREATED WITH SHORT-, INTERMEDIATE-AND LONG-ACTING STIMULANTS
Christensen L 1 , Sasane R 2 , Hodgkins P 2 , Harley C 3 1 i3 Innovus, Ann Arbor, MI, USA, 2 Shire Pharmaceuticals, Wayne, PA, USA, 3 i3 Innovus, Eden Prairie, MN, USA OBJECTIVES: This research examines the relationship of ethnicity and income with attention-defi cit hyperactivity disorder (ADHD) treatment patterns among subjects on medications of different durations. METHODS: Claims of newly treated ADHD subjects, aged 6 years, initially treated with stimulants, and continuously enrolled in a US commercial health plan 6 months prior and 12 months after their fi rst prescription (January 1, 2004 "C September 30, 2006 were studied. Subjects took short-(SAS) intermediate-(IAS) or long-acting (LAS) stimulant medication for ADHD. Persistence was defi ned as the number of days on initial therapy. Adherence was defi ned as the number of days of initial therapy divided by persistent days. Differences in mean persistence and adherence, dosing, switching and augmentation among ethnicities (non-Hispanic Caucasians [NHC], Hispanics [H] and African Americans [AA]) and among income levels were assessed. RESULTS: Among children on LAS (n 12,796), NHC had the highest mean adherence (0.56) and the longest mean persistence (251 days) (p 0.0001 among groups), while AA had the shortest persistence (222 days) and the lowest adherence (0.46) (p 0.0001 among groups). Similarly, among adults receiving LAS (n 8422), NHC had the highest adherence (0.58) and the longest persistence (225 days). Persistence was again shortest among AA (194 days; p 0.037 among groups), while adherence was equally low for AA and H (0.52; p 0.002 among groups). Within treatment groups of different durations, the propensity of subjects to change dose, switch or augment their medication varied according to ethnicity. While no signifi cant relationship between race/ethnicity and either adherence or persistence was found among children or adults receiving SAS or IAS, the IAS and LAS groups showed greater persistence and adherence with increased income levels in some subjects. CONCLUSIONS: Persistence and adherence to stimulant medications differed by race/ethnicity and income. This may have implications for the optimal management of ADHD.
PMH88 A SYSTEMATIC EVALUATION OF PUBLISHED LITERATURE TO ASSESS BURDEN OF TREATMENT-RESISTANT DEPRESSION
Cyr P y 1 , Bockstedt L 2 , Olchanski N 1 , Halseth M 2 , Partlow K 3 , Lindeke C 2 , Handke B 2 , Goss T 3 1 Boston Healthcare Associates, Inc, Boston, MA, USA, 2 Medtronic Neuromodulation, Fridley, MN, USA, 3 Boston Healthcare Associates, Inc, Washington, DC, USA BACKGROUND: Treatment-resistant depression (TRD) is severely disabling with no treatments proven to provide sustainable benefi t when multiple medications, psychotherapy, and electroconvulsive therapy fail. (Malone, 2008) . OBJECTIVES: The perform a systematic review of published literature to evaluate recent health economics and outcomes research related to TRD to inform future research initiatives. METHODS: English language citations in PubMed and Cochrane Library from January 1, 2000-October 1, 2008 were systematically reviewed. Standard search terms defi ned disease states (including TRD, severe depression (SD), chronic depression (CD), major depressive disorders (MDD), and suicidality); interventions (deep brain stimulation, electroconvulsive therapy, transcranial magnetic stimulation and vagus nerve stimulation); and outcomes (treatment outcomes, presenteeism, symptom burden, resource utilization, productivity, cost, economics, and quality of life(QOL)). RESULTS: Initial searches yielded 8811 citations, narrowed to 5626 using date and language criteria. Title review further narrowed literature (reasons: not related to depression 70%, clinical trials of antidepressant medications 20%, and review/case studies 10%), resulting in 411 unique abstracts for review and forty publications for abstraction. Clinical studies were most frequent (n 16) and economic models least frequent (n 3); a majority (n 22) reported a U.S. patient population. Thirteen publications reported on TRD, thirteen on MDD, and six reported on a "general depression" population. Reported defi nitions of TRD varied greatly (one medication failure (n 2), two medication failures (n 6), HAM-D score (n 3), diagnosis/treatment algorithm (n 1), not defi ned (n 1)). HAM-D (n 12) and MADRS (n 9) were the most frequently reported clinical outcomes measures. Cost outcomes were discussed in thirteen reports (direct costs (n 11), indirect costs (n 2)). CONCLU-SIONS: Defi nitions of TRD or CD reported in the literature vary substantially, and studies examining productivity of patients were confi ned to generic depression or MDD populations and would not be directly comparable to a CD or TRD population. Additional research is necessary to better defi ne the cost and patient burden of TRD.
NEUROLOGICAL DISORDERS -Clinical Outcomes Studies

PND1 PREVALENCE OF INSOMNIA IN EUROPE: A COMPARISON OF FIVE COUNTRIES
Narayanan S y 1 , Potthoff P 2 , Guether B 2 1 TNS Healthcare, New York, NY, USA, 2 TNS Healthcare, Munich, Bavaria, Germany OBJECTIVES: To assess the prevalence of insomnia among fi ve large European nations. METHODS: TNS Healthcare's European Healthcare Panel of individuals in France, Germany, Italy, UK and the Netherlands were surveyed in 2007 to assess disease burden at national level. The self-reported epidemiological data is representative of population gender and age (18-24,25-34,35-44,45-54,55-64,65-69yrs ) strata in respective countries, ensured by sampling and intensive panel management. The survey collected information on select health conditions (incl. insomnia/sleepingproblems; in the past 12-months), quality of life and health care-utilization. RESULTS: Total of over 160,000 adult individuals in the European Healthcare Panel completed survey in the fi ve European nations. Prevalence of Insomnia varied widely between these 5 nations, as follows (All, Male, Female, % individuals): Netherlands: 13.5%,9.2%,18.0%; Italy: 18.5%,13.3%,23.6%; U.K: 19.3%,14.7%,24.0%; Germany: 21.6%,16.2%,27.0%; France: 27.6%,19.9%,35.0%. Within each country, burden of Insomnia varied by age and gender; distribution among male (18-24, 25-34,35-44,45-54,55-64,65 yrs: % pts) was: the Netherlands: 6.4%,8.5%,8.1%, 10.9%,11.0%,8.9%; Italy: 11.1%,8. 9%, 12.6%, 15.7%, 16.1%, 18.9%; U.K: 9.8%, 10.8%, 16.6%, 18.1%, 17.0%, 12.9%; Germany: 12.8%, 14.1%, 17.1%, 19.6%, 18.0%, 11.6%; France: 15.9%, 17.8%, 21.2%, 24.0%, 19.5%, 18.9%; [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] 65 yrs: % pts) was: the Netherlands: 8. 5%, 12.5%, 15.5%, 23.7%, 23.4%, 25.6%; Italy: 16.9%, 19.1%, 22.4%, 28.0%, 27.2%, 27.2%; U.K: 17.1%, 18.2%, 23.0%, 30.1%, 30.0%, 24.8%; Germany: 23.3%, 23.5%, 26.5%, 32.0%, 27.6%, 26.2%; France: 28.5%, 29.6%, 34.2%, 39.9%, 40.3%, 37 .2%. General Practitioners were the primary point of diagnosis and source of treatment, even though this statistic varied between the countries. CONCLUSIONS: Prevalence of insomnia appears to be substantial in the studied European nations, with France bearing the most burden (one-in-fi ve and one-in-three males and females respectively in France suffered from this condition). Prevalence peaked among the 45-64 age-group across the countries. Females had substantially higher disease burden across the countries, amounting to as much as 1.5 to 2 times more than their male counterparts in certain age groups.
PND2 CHRONIC MIGRAINE CRITERIA AND THEIR EFFECTS ON GLOBAL PREVALENCE ESTIMATES: A SYSTEMATIC REVIEW
Natoli JL J 1 , Manack A 2 , Dean BB 1 1 Cerner LifeSciences, Beverly Hills, CA, USA, 2 Allergan, Inc., Irvine, CA, USA OBJECTIVES: The defi nition of chronic migraine (CM), as opposed to episodic migraine, has evolved over 20 years of clinical study. This systematic review summarized population-based studies reporting CM prevalence and examined how variations in defi nitions affected estimates. METHODS: We conducted a systematic search of PubMed, Cochrane, and EMBASE. Search terms included chronic migraine, transformed migraine, chronic headache, and prevalence. We included populationbased studies in adults and mixed adults/adolescents that estimated CM prevalence (or provided information to calculate estimates). We defi ned chronicity as a minimum headache frequency of 10 per month or reported "daily" headache. Where equivalent, we combined diagnostic criteria and defi nitions. Findings were qualitatively summarized. RESULTS: Sixteen publications representing 12 unique studies were identifi ed.
